- Email: [email protected]
Efficacy and safety of eye serums formulated for use with a sonic applicator
P6233
P6943
CosmeceutiQoL: A dermocosmetic quality-of-life assessment tool Charles-Remy Taieb, MD, MBA, CREES PFSA, Boulogne Billancourt, France; Nuria Perez-Cullell, PharmD, Eau Thermale Avene, Lavaur, France Background: For more than 40 years, ‘‘dermocosmetics’’ or ‘‘cosmeceuticals’’ have been identified with the field of cosmetics and hygiene products adhering to the rules of good practice of pharmaceutical science. Paradoxically, while ‘‘dermocosmetics’’ or ‘‘cosmeceuticals’’ are developing and now concern all age groups of the population, there is no quality-of-life questionnaire available to assess the impact of this treatment on quality of life. The evaluation of its impact in terms of quality of life is however a bold, ambitious, and also necessary step. The CosmeceutiQoL has arrived to fill this gap. Totaling a maximum of 100, the CosmeceutiQoL score increases with quality of life. Objective: The objective of this evaluation was to test the CosmeceutiQoL’s sensitivity to change in women using a dermocosmetic.
Efficacy and safety of lipohydroxy acid combined with trichloracetic acid facial peel Charitomeni Vavoulis, Andreas Sygros Hospital, Athens, Greece; Evgenia Balamotis, Andreas Sygros Hospital, Athens, Greece; Georgios Kontochristopoulos, PhD, Andreas Sygros Hospital, Athens, Greece; Vasiliki Markantonis, Andreas Sygros Hospital, Athens, Greece
Methods: Women aged 22 to 66 years and users of Tolerance Extreme DEFI were recruited in French pharmacies. They completed the CosmeceutiQoL on inclusion and on the 7th and 14th day. An irritability and Sensiscale score were also taken. Results: 44 women aged 22 to 66 years. 72% report using day cream, 42% a night cream. The irritability score, measured using a visual analog scale, was 4.2 at baseline. Sensitivity, measured using the Sensiscale, was 43.3 at baseline. The CosmeceutiQoL score was 42.5.On the 7th and 14th days, the irritability score was 2.39 and 1.23 and the Sensiscale was 19.80 and 7.03 respectively. During the same time interval, the CosmeceutiQoL scores were 53 and 71. For the 3 scores, there was a statistically significant improvement in the score from the 7th day. This improvement was confirmed on the 14th day. There were no significant differences according to the patient’s age. Discussion: The CosmeceutiQoL questionnaire was created and validated in 2010. Its objective was to assess a dermocosmetic’s impact on the quality of life of women. The significant improvement in the score from the 7th day, maintained on the 14th day, confirms the relevance of this questionnaire. Conclusion: The CosmeceutiQoL’s reproducibility was confirmed during questionnaire validation, and this evaluation validates sensitivity to change. Supported by Eau Thermale Avene.
Background: Lipohydroxy acid (LHA) is a new salicylic acid derivative with keratolytic, comedolytic, sebostatic, antiinflammatory, and antimicrobial properties. Trichloracetic acid (TCA) is the criterion standard of chemical peeling, inducing superficial coagulation of skin proteins, thereby promoting dermal regeneration with new collagen deposition. The present study evaluates the efficacy and safety of a superficial to medium depth chemical peeling that combines LHA and TCA for the treatment of acne, acne scars, melasma, dyschromias, and photodamage. Methods: Forty-three patients (38 females and 5 males), aged between 14 to 71years, classed Fitzpatrick as II to IV, were included in the study. Ten patients had acne and 11 had acne scars, 13 displayed photoaging, and 9 superficial melasma. Informed consent was obtained from each patient after explanation of the procedure. A detailed history was taken and clinical examination was performed under natural light by a team of dermatologists. Four monthly peeling sessions were carried out on each patient. Patients with acne and melasma were subjected to peeling with LHA 10% combined with TCA 15%. Acne scars and photoaging were treated with LHA 10% followed by TCA 25% concentration. Cosmetic improvement was evaluated by patients, investigators, and by means of photographs. Safety was assessed by evaluating adverse events, such as erythema, edema, epidermal necrosis, or other irritating reactions. Results: Most patients showed significant improvement. Clinical efficacy of treatment for acne was evaluated 62%, 52% for acne scars, 67% for superficial melasma, and almost 70% for photoaging. The procedure was well tolerated. Mild discomfort and transient erythema were quite common (90%), but no major side effects were reported. Conclusion: This combination of peeling agents enhanced the depth of the peel and improved the therapeutic effect with the use of low concentration of the peeling agent. The epidermis has been made more permeable by the LHA peel, and we can use a low concentration solution of TCA, incurring only mild temporary adverse effects. Commercial support: None identified.
P6742 Efficacy and safety of eye serums formulated for use with a sonic applicator Matt Winterscheid, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Emily Henes, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Emily Henes, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Greg Peterson, PhD, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Katherine Ortblad, MBA, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Micheal Kearney, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Nina Koski, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States Background: Eye serums (ES) are applied to the delicate skin under the eye to help firm, brighten, and provide restorative benefits bringing life to dull, tired looking eyes. A very gentle tapping motion of the ring finger or use of a sonic applicator (SA) are used to apply ES. The SA generates gentle sonic pulses that rapidly (but gently) apply eye serums/creams to outer most layers of the stratum corneum that simulate the ring finger motion of application. Two difference ES (an antiaging sea and Pro RT3 serum) have been formulated to be applied with the SA. The purpose of the study was to clinically assess efficacy and safety of the ES when applied with the SA via measurements of skin hydration [H (Corneometer)], user perception (questionnaire), and before/after photographs over an 8-week period. Methods: The ES were evaluated in a parallel arm, blinded, randomized 8-week home use study (n ¼ 88). Women with visible signs associated with aging between the ages of 35 and 65, participated in the 3-visit study. Subjects were randomized to 1 of 2 specially formulated ES to be used with the SA. At baseline, the study examiner used the SA to apply the randomized ES to the left under eye area for 30 seconds. Subjects used the SA to apply the ES to the right under eye area for 30 seconds. H was measured at baseline (before and 15 minutes after product use). Photographs and completion of a questionnaire at each study visit were obtained to assess efficacy and safety. Subjects were instructed to use the SA/ES at home twice per day (morning/bedtime).
P6945 Efficacy of a new lightening skin care routine on facial hyperpigmentation versus 1 intense pulsed laser (IPL) therapy Yan Li, Hospital of China Medical University, Shenyang, China; Alice Laurent, L’Oreal Research and Innovation, Chevilly-La-Rue, France; Elisabeth Bouhadana, L’Oreal Paris, Clichy, France; Frederic Flament, L‘Oreal Research and Innovation, Chevilly-La-Rue, France; Marie-Helene Gaudinat, L’Oreal Paris, Clichy, France; Pascale Piquemal, L’Oreal Research and Innovation, Chevilly-La-Rue, France
Results: Results were compared statistically using a paired t test. A statistically significant increase (P \.001) in H was measured after 15 minutes of use for both ES and majority of subjects perceived their skin was more hydrated in areas where the ES was applied (95%: antiaging sea serum; 92%: Pro RT3 serum). Majority of subjects perceived their skin had reduction in fine lines/wrinkles (92%: antiaging sea serum; 82%: Pro RT3 serum), and more elasticity or firmness (90%: antiaging sea serum; 84%: Pro RT3 serum) in areas where the ES was applied with the SA. Conclusion: The study confirmed safety and efficacy of the study ES when applied to the delicate under area using the SA.
Facial hyperpigmentation, a patchy discoloration of skin resulting from variations in pigment density mainly caused by accumulative sun exposure and hormonal factors, is a rather common clinical picture in Asian people. In many cases, this dyschromic condition can be improved by the use of lightening skin care products. The effects of a cosmetic whitening routine combining a spot corrector essence and a whitening SPF cream were compared with 1 intense pulsed laser (IPL) therapy, a well known dermatologic practice in the treatment of hyperpigmentation. This controlled single-center, randomized, parallel group trial was carried out in 90 female volunteers, 35 to 65 years of age (average, 49.3 years of age), with Fitzpatrick skin types III to IV showing facial hyperpigmentation. The efficacy and tolerance of daily combined application of a spot corrector (ellagic acid + calcium pantheteine sulfonate) and a SPF 19 whitening cream containing lipohydroxy acid, vitamin B3, and procystein for a 2-month period were compared with 1 IPL session followed by daily application of a moisturizer as a topical placebo for 2 months. The clinical improvement in both the intensity and size of a selected dark spot was evaluated on weeks 4 and 8 with visual scoring (0 to 9) and measurement (size expressed in mm) of the selected spot. Clinical grading (0 to 9) of skin smoothness, radiance, and texture on the face was made on weeks 4 and 8. Cross-polarized digital photographs of the face and Chromameter measurements were also used for assessing intensity and size of selected dark spot. Volunteers completed a self-assessment questionnaire on day 7 and at each study visit clinical scoring results on W8 indicate that IPL and skin care significantly reduced intensity (-0.88 and -0.95, respectively) and size (-0.35 and -0.38 mm, respectively) of facial dark spots. There was a significant improvement in skin radiance (+1.19 and +2), texture, and roughness with both treatments, with a statistically significant difference in favor of the cosmetic routine for skin radiance. Chromametry confirmed the significant lightening effect on dark spots for both treatments. No statistical difference was observed between the 2 treatments in any dyschromia criteria, suggesting that the combined cosmetic skincare routine (spot corrector and SPF 19 whitening cream) shows a comparable efficacy versus 1 IPL session in subjects with facial hyperpigmentation.
100% sponsored by Pacific Bioscience Laboratories, Inc.
50% supported by L’Oreal Research.
APRIL 2013
J AM ACAD DERMATOL
AB23
P6943
CosmeceutiQoL: A dermocosmetic quality-of-life assessment tool Charles-Remy Taieb, MD, MBA, CREES PFSA, Boulogne Billancourt, France; Nuria Perez-Cullell, PharmD, Eau Thermale Avene, Lavaur, France Background: For more than 40 years, ‘‘dermocosmetics’’ or ‘‘cosmeceuticals’’ have been identified with the field of cosmetics and hygiene products adhering to the rules of good practice of pharmaceutical science. Paradoxically, while ‘‘dermocosmetics’’ or ‘‘cosmeceuticals’’ are developing and now concern all age groups of the population, there is no quality-of-life questionnaire available to assess the impact of this treatment on quality of life. The evaluation of its impact in terms of quality of life is however a bold, ambitious, and also necessary step. The CosmeceutiQoL has arrived to fill this gap. Totaling a maximum of 100, the CosmeceutiQoL score increases with quality of life. Objective: The objective of this evaluation was to test the CosmeceutiQoL’s sensitivity to change in women using a dermocosmetic.
Efficacy and safety of lipohydroxy acid combined with trichloracetic acid facial peel Charitomeni Vavoulis, Andreas Sygros Hospital, Athens, Greece; Evgenia Balamotis, Andreas Sygros Hospital, Athens, Greece; Georgios Kontochristopoulos, PhD, Andreas Sygros Hospital, Athens, Greece; Vasiliki Markantonis, Andreas Sygros Hospital, Athens, Greece
Methods: Women aged 22 to 66 years and users of Tolerance Extreme DEFI were recruited in French pharmacies. They completed the CosmeceutiQoL on inclusion and on the 7th and 14th day. An irritability and Sensiscale score were also taken. Results: 44 women aged 22 to 66 years. 72% report using day cream, 42% a night cream. The irritability score, measured using a visual analog scale, was 4.2 at baseline. Sensitivity, measured using the Sensiscale, was 43.3 at baseline. The CosmeceutiQoL score was 42.5.On the 7th and 14th days, the irritability score was 2.39 and 1.23 and the Sensiscale was 19.80 and 7.03 respectively. During the same time interval, the CosmeceutiQoL scores were 53 and 71. For the 3 scores, there was a statistically significant improvement in the score from the 7th day. This improvement was confirmed on the 14th day. There were no significant differences according to the patient’s age. Discussion: The CosmeceutiQoL questionnaire was created and validated in 2010. Its objective was to assess a dermocosmetic’s impact on the quality of life of women. The significant improvement in the score from the 7th day, maintained on the 14th day, confirms the relevance of this questionnaire. Conclusion: The CosmeceutiQoL’s reproducibility was confirmed during questionnaire validation, and this evaluation validates sensitivity to change. Supported by Eau Thermale Avene.
Background: Lipohydroxy acid (LHA) is a new salicylic acid derivative with keratolytic, comedolytic, sebostatic, antiinflammatory, and antimicrobial properties. Trichloracetic acid (TCA) is the criterion standard of chemical peeling, inducing superficial coagulation of skin proteins, thereby promoting dermal regeneration with new collagen deposition. The present study evaluates the efficacy and safety of a superficial to medium depth chemical peeling that combines LHA and TCA for the treatment of acne, acne scars, melasma, dyschromias, and photodamage. Methods: Forty-three patients (38 females and 5 males), aged between 14 to 71years, classed Fitzpatrick as II to IV, were included in the study. Ten patients had acne and 11 had acne scars, 13 displayed photoaging, and 9 superficial melasma. Informed consent was obtained from each patient after explanation of the procedure. A detailed history was taken and clinical examination was performed under natural light by a team of dermatologists. Four monthly peeling sessions were carried out on each patient. Patients with acne and melasma were subjected to peeling with LHA 10% combined with TCA 15%. Acne scars and photoaging were treated with LHA 10% followed by TCA 25% concentration. Cosmetic improvement was evaluated by patients, investigators, and by means of photographs. Safety was assessed by evaluating adverse events, such as erythema, edema, epidermal necrosis, or other irritating reactions. Results: Most patients showed significant improvement. Clinical efficacy of treatment for acne was evaluated 62%, 52% for acne scars, 67% for superficial melasma, and almost 70% for photoaging. The procedure was well tolerated. Mild discomfort and transient erythema were quite common (90%), but no major side effects were reported. Conclusion: This combination of peeling agents enhanced the depth of the peel and improved the therapeutic effect with the use of low concentration of the peeling agent. The epidermis has been made more permeable by the LHA peel, and we can use a low concentration solution of TCA, incurring only mild temporary adverse effects. Commercial support: None identified.
P6742 Efficacy and safety of eye serums formulated for use with a sonic applicator Matt Winterscheid, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Emily Henes, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Emily Henes, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Greg Peterson, PhD, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Katherine Ortblad, MBA, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Micheal Kearney, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States; Nina Koski, Pacific Bioscience Laboratories, Inc, Redmond, WA, United States Background: Eye serums (ES) are applied to the delicate skin under the eye to help firm, brighten, and provide restorative benefits bringing life to dull, tired looking eyes. A very gentle tapping motion of the ring finger or use of a sonic applicator (SA) are used to apply ES. The SA generates gentle sonic pulses that rapidly (but gently) apply eye serums/creams to outer most layers of the stratum corneum that simulate the ring finger motion of application. Two difference ES (an antiaging sea and Pro RT3 serum) have been formulated to be applied with the SA. The purpose of the study was to clinically assess efficacy and safety of the ES when applied with the SA via measurements of skin hydration [H (Corneometer)], user perception (questionnaire), and before/after photographs over an 8-week period. Methods: The ES were evaluated in a parallel arm, blinded, randomized 8-week home use study (n ¼ 88). Women with visible signs associated with aging between the ages of 35 and 65, participated in the 3-visit study. Subjects were randomized to 1 of 2 specially formulated ES to be used with the SA. At baseline, the study examiner used the SA to apply the randomized ES to the left under eye area for 30 seconds. Subjects used the SA to apply the ES to the right under eye area for 30 seconds. H was measured at baseline (before and 15 minutes after product use). Photographs and completion of a questionnaire at each study visit were obtained to assess efficacy and safety. Subjects were instructed to use the SA/ES at home twice per day (morning/bedtime).
P6945 Efficacy of a new lightening skin care routine on facial hyperpigmentation versus 1 intense pulsed laser (IPL) therapy Yan Li, Hospital of China Medical University, Shenyang, China; Alice Laurent, L’Oreal Research and Innovation, Chevilly-La-Rue, France; Elisabeth Bouhadana, L’Oreal Paris, Clichy, France; Frederic Flament, L‘Oreal Research and Innovation, Chevilly-La-Rue, France; Marie-Helene Gaudinat, L’Oreal Paris, Clichy, France; Pascale Piquemal, L’Oreal Research and Innovation, Chevilly-La-Rue, France
Results: Results were compared statistically using a paired t test. A statistically significant increase (P \.001) in H was measured after 15 minutes of use for both ES and majority of subjects perceived their skin was more hydrated in areas where the ES was applied (95%: antiaging sea serum; 92%: Pro RT3 serum). Majority of subjects perceived their skin had reduction in fine lines/wrinkles (92%: antiaging sea serum; 82%: Pro RT3 serum), and more elasticity or firmness (90%: antiaging sea serum; 84%: Pro RT3 serum) in areas where the ES was applied with the SA. Conclusion: The study confirmed safety and efficacy of the study ES when applied to the delicate under area using the SA.
Facial hyperpigmentation, a patchy discoloration of skin resulting from variations in pigment density mainly caused by accumulative sun exposure and hormonal factors, is a rather common clinical picture in Asian people. In many cases, this dyschromic condition can be improved by the use of lightening skin care products. The effects of a cosmetic whitening routine combining a spot corrector essence and a whitening SPF cream were compared with 1 intense pulsed laser (IPL) therapy, a well known dermatologic practice in the treatment of hyperpigmentation. This controlled single-center, randomized, parallel group trial was carried out in 90 female volunteers, 35 to 65 years of age (average, 49.3 years of age), with Fitzpatrick skin types III to IV showing facial hyperpigmentation. The efficacy and tolerance of daily combined application of a spot corrector (ellagic acid + calcium pantheteine sulfonate) and a SPF 19 whitening cream containing lipohydroxy acid, vitamin B3, and procystein for a 2-month period were compared with 1 IPL session followed by daily application of a moisturizer as a topical placebo for 2 months. The clinical improvement in both the intensity and size of a selected dark spot was evaluated on weeks 4 and 8 with visual scoring (0 to 9) and measurement (size expressed in mm) of the selected spot. Clinical grading (0 to 9) of skin smoothness, radiance, and texture on the face was made on weeks 4 and 8. Cross-polarized digital photographs of the face and Chromameter measurements were also used for assessing intensity and size of selected dark spot. Volunteers completed a self-assessment questionnaire on day 7 and at each study visit clinical scoring results on W8 indicate that IPL and skin care significantly reduced intensity (-0.88 and -0.95, respectively) and size (-0.35 and -0.38 mm, respectively) of facial dark spots. There was a significant improvement in skin radiance (+1.19 and +2), texture, and roughness with both treatments, with a statistically significant difference in favor of the cosmetic routine for skin radiance. Chromametry confirmed the significant lightening effect on dark spots for both treatments. No statistical difference was observed between the 2 treatments in any dyschromia criteria, suggesting that the combined cosmetic skincare routine (spot corrector and SPF 19 whitening cream) shows a comparable efficacy versus 1 IPL session in subjects with facial hyperpigmentation.
100% sponsored by Pacific Bioscience Laboratories, Inc.
50% supported by L’Oreal Research.
APRIL 2013
J AM ACAD DERMATOL
AB23